Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F24%3A10485855" target="_blank" >RIV/00216208:11110/24:10485855 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=C2X_NmI2K5" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=C2X_NmI2K5</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00384-024-04727-3" target="_blank" >10.1007/s00384-024-04727-3</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab

Popis výsledku v původním jazyce

Purpose: Immunogenicity is a major reason for secondary loss of response to infliximab (IFX). Recent work suggested potentially lower immunogenicity of subcutaneous (SC) compared to intravenous (IV) IFX. However, it is unknown whether re-exposure to IFX SC after secondary loss of response and immunogenicity to its intravenous formulation is safe and effective. Methods: In a retrospective cohort study conducted at two medical centers, patients with clinically (Harvey-Bradshaw Index &gt;= 5) and/or biochemically (fecal calprotectin &gt; 250 µg/g) active Crohn&apos;s disease (CD) and previous immunogenic failure of IFX IV underwent exposure to IFX SC. Harvey-Bradshaw Index, fecal calprotectin, IFX serum concentration, and anti-drug antibodies were assessed until month 12. Results: Twenty CD patients were included. The majority of patients (90%) had previous treatment with three or more biologics. Fifteen (75%) and ten (50%) of 20 patients continued IFX SC treatment until months 6 and 12, respectively. No immediate hypersensitivity reactions were observed. Two patients discontinued IFX SC treatment because of delayed hypersensitivity at week 2 and week 4. IFX serum concentrations increased from baseline to month 12, while anti-drug antibody levels decreased. Combined clinical and biochemical remission at month 12 was observed in seven of 20 patients (35%). Conclusion: Subcutaneous infliximab treatment of Crohn&apos;s disease patients with previous immunogenic failure of intravenous infliximab was well tolerated and effective in a cohort of patients with refractory Crohn&apos;s disease.

Název v anglickém jazyce

Subcutaneous infliximab in Crohn's disease patients with previous immunogenic failure of intravenous infliximab

Popis výsledku anglicky

Purpose: Immunogenicity is a major reason for secondary loss of response to infliximab (IFX). Recent work suggested potentially lower immunogenicity of subcutaneous (SC) compared to intravenous (IV) IFX. However, it is unknown whether re-exposure to IFX SC after secondary loss of response and immunogenicity to its intravenous formulation is safe and effective. Methods: In a retrospective cohort study conducted at two medical centers, patients with clinically (Harvey-Bradshaw Index &gt;= 5) and/or biochemically (fecal calprotectin &gt; 250 µg/g) active Crohn&apos;s disease (CD) and previous immunogenic failure of IFX IV underwent exposure to IFX SC. Harvey-Bradshaw Index, fecal calprotectin, IFX serum concentration, and anti-drug antibodies were assessed until month 12. Results: Twenty CD patients were included. The majority of patients (90%) had previous treatment with three or more biologics. Fifteen (75%) and ten (50%) of 20 patients continued IFX SC treatment until months 6 and 12, respectively. No immediate hypersensitivity reactions were observed. Two patients discontinued IFX SC treatment because of delayed hypersensitivity at week 2 and week 4. IFX serum concentrations increased from baseline to month 12, while anti-drug antibody levels decreased. Combined clinical and biochemical remission at month 12 was observed in seven of 20 patients (35%). Conclusion: Subcutaneous infliximab treatment of Crohn&apos;s disease patients with previous immunogenic failure of intravenous infliximab was well tolerated and effective in a cohort of patients with refractory Crohn&apos;s disease.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30219 - Gastroenterology and hepatology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Colorectal Disease

ISSN

0179-1958

e-ISSN

1432-1262

Svazek periodika

39

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

8

Strana od-do

151

Kód UT WoS článku

001319793400001

EID výsledku v databázi Scopus

2-s2.0-85204900025